Arrowhead’s Redemplo Faces Competition After Rival’s Tryngolza FDA Approval with 72% Triglyceride Cut
ARWR•The FDA approved Ionis’s Tryngolza as first treatment reducing triglycerides by up to 72% and acute pancreatitis events by up to 91%, with U.S. launch set for July. Rival Arrowhead Pharmaceuticals’s Redemplo now faces direct competition in the sHTG market, potentially pressuring its future market share and valuation.
1. FDA Approval of Tryngolza
The FDA granted broad label approval for Tryngolza in severe hypertriglyceridemia, marking it as the first therapy indicated to reduce both triglycerides and acute pancreatitis risk. Late-stage CORE and CORE2 trials demonstrated up to 72% triglyceride reduction at six months and a 91% drop in pancreatitis events.
2. Competitive Pressure on Redemplo
Arrowhead Pharmaceuticals’s investigational drug Redemplo targets the same sHTG indication and now faces head-to-head competition from Tryngolza. Ionis’s first-mover advantage and robust clinical data heighten the challenge for Redemplo to differentiate its efficacy and safety profile.
3. Market Launch and Commercial Outlook
Ionis plans a July U.S. launch of Tryngolza, delivered via once-monthly 50 mg or 80 mg autoinjector, with an addressable patient population exceeding three million. Pricing and uptake dynamics in the sHTG segment will be crucial variables impacting Arrowhead’s forecasted revenue potential.
4. Analyst Response and Investor Reaction
Goldman Sachs raised Ionis’s price target to $75, sending Ionis shares up 4% after-hours. This positive sentiment underscores investor confidence in Tryngolza’s market impact and may prompt renewed scrutiny of Arrowhead’s development timeline and valuation assumptions.
